European Companies Search Engine
EU funding (€3,746,804): Advancing European Research Infrastcuture on Highly Pathogenic Agents Hor 10 Dec 2018 EU Research and Innovation programme "Horizon"
Text
Advancing European Research Infrastcuture on Highly Pathogenic Agents
One of the great challenges of the 21st century is to develop the capacity to prevent and react to outbreaks caused by highly pathogenic human and animal microorganisms, which are generally characterized by a high mortality rate, unavailability of prophylactics or effective therapeutic treatment and high human-to-human transmission. ERINHA AISBL (European Research Infrastructure on Highly Pathogenic Agents), a pan-European Research Infrastructure (RI) dedicated to the study of high-consequence pathogens of Risk Group 4 (RG4), entered into implementation phase in July 2017. It now aims to ensure its long-term sustainability to better answer societal challenges in the field of Science, Health and Security. The overall aim of the ERINHA-Advance project is to implement actions that will contribute to the long-term sustainability of the ERINHA RI, through enlargement of its membership and partnership and strengthening the overall services offer and framework by fostering the innovation potential of the RI. To reach these goals, the RI will focus on the following specific objectives: 1. Enlarge ERINHA’s membership and research capacities (WP2); 2. Improve users services (WP3); 3. Stimulate the innovation potential of ERINHA and identify the co-innovation opportunities with industry (WP4); 4. Strengthen the overall services framework through long-term data-management and data sharing rules, clarification of IPR regimes and definition and implementation of the quality assurance system of the RI and its national nodes (WP5); 5. Reinforce ERINHA’s European and International cooperation with relevant countries, initiatives and networks (WP2 and WP6). By achieving these objectives, ERINHA-Advance will largely contribute to providing access to larger number of high containment facilities to European and international scientists and foster research and innovation in the field of highly infectious diseases.
Funded Companies:
| Company name | Funding amount |
| Bernhard-Nocht-Institut Fuer Tropenmedizin | €43,750 |
| Erasmus Universitair Medisch Centrum Rotterdam | €115,881 |
| European Research Infrastructure ON Highly Pathogenic Agents | €1,763,143 |
| Folkhalsomyndigheten | €342,500 |
| Inserm Transfert SA | €283,250 |
| Institut National de la Sante et de la Recherche Medicale | €371,250 |
| Instituto Nacional de Saude DR. Ricardo Jorge | €210,724 |
| Istituto Nazionale Per LE Malattie Infettive Lazzaro Spallanzani-Istituto Di Ricovero E Cura A Carattere Scientifico | €79,037 |
| Karolinska Institutet | €81,498 |
| Katholieke Universiteit Leuven | €104,368 |
| Medizinische Universitat Graz | €92,950 |
| Nemzeti Nepegeszsegugyi ES Gyogyszereszeti Kozpont | €258,452 |
Source: https://cordis.europa.eu/project/id/824061
The filing refers to a past date, and does not necessarily reflect the current state.
